Concis Labs Information

State Medicaid committees quietly shape drug access for over 90 million Americans. Preferred drug lists shift. Prior authorizations appear. Coverage criteria change — often with little notice and less transparency. Concis·Labs was built to fix that blind spot. We have eyes and ears in every P&T, DUR, PDAC, and RDAC committee across the country. We capture the discussions, extract the signals, and deliver actionable intelligence directly to pharma market access teams — in real time, not weeks later. Our clients don't just track formulary changes. They anticipate them. When Florida adds a prior authorization to a drug class, they already know which ten states are likely to follow. Searchable meeting archives. Real-time alerts. Competitive intelligence that compounds over time. Built for pharma and biotech VPs, executive directors, and market access leaders who need to move faster than the regulatory landscape. concislabs.com